Immune cell engineering for cancer therapy

Submission status
Submission deadline

Chimeric antigen receptor (CAR) T cell therapies have revolutionized the treatment of haematological malignancies; however, their application in solid tumors remains challenging. CAR technology has now extended beyond T-cells and applied to other immune cells, including NK cells and macrophages. Alternative immune-engineering approaches, including direct in vivo immune cell engineering, are also emerging. A tumor infiltrating lymphocyte (TIL)-based therapy has recently received FDA approval as the first cellular therapy for solid tumors.

With this Collection, a partnership between Nature Communications, Communications Medicine, Communications Biology and Scientific Reports, we welcome submissions of primary research papers that focus on immune cell engineering for cancer therapy. The journals are particularly interested in preclinical studies proposing new engineering strategies and therapeutic developments.

Nature Communications, Communications Medicine, and Scientific Reports are also interested in publishing high-quality clinical research in the field.

We will highlight relevant papers in this Collection; unfortunately, we cannot guarantee that any individual paper will be included in the Collection.

To submit, see the participating journals
Chimeric antigen receptor CAR - car T-Cell therapy, CAR T-cell therapy is the use of genetically modified T cells that express a special protein called a chimeric antigen receptor 3d rendering

Reviews, Analysis, News and Comment

Clinical and translational research

Preclinical development